Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.

Abstract:

OBJECTIVE:Addressing the needs of migraineurs by actively seeking patient feedback on disease-related disability and treatment satisfaction may lead to improved management and treatment outcomes. Patient feedback can be collected in postmarketing surveillance (PMS) studies. The objective of this PMS study was to evaluate the efficacy and tolerability of zolmitriptan 5 mg nasal spray in the acute treatment of migraine attacks. PATIENTS AND METHODS:Patients received zolmitriptan 5 mg nasal spray to treat migraine attacks of any severity and were followed up after a maximum of 4 months. Patients evaluated the efficacy and tolerability of zolmitriptan nasal spray, and were asked whether they wished to continue using zolmitriptan nasal spray and their preference compared with previous treatments. Physicians also assessed the efficacy and tolerability of zolmitriptan nasal spray. RESULTS:A total of 1838 patients (84.8% females) participated in the study. Within 30 minutes of administration of zolmitriptan nasal spray, 85.0% of patients reported improvements in headache pain, with 25.1% reporting an improvement within 10 minutes. At 1 hour post-dose, 57.9% of patients were pain free and 61.7% were able to resume usual daily activities. Most patients (72.9%) rated zolmitriptan nasal spray as 'better' than previous therapy. The majority (88.8%) expressed a wish to continue using zolmitriptan nasal spray. Physicians evaluated the efficacy of zolmitriptan nasal spray as 'excellent' or 'good' in 89.4% of patients. Tolerability was evaluated as 'excellent' or 'good' in 91.6% of patients. CONCLUSIONS:Zolmitriptan 5 mg nasal spray provides favourable efficacy and tolerability in the acute treatment of migraine attacks. Most patients assessed zolmitriptan nasal spray as 'better' than previous treatment, with nearly all wishing to continue using it.

journal_name

Clin Drug Investig

authors

Diener HC,Evers S

doi

10.2165/00044011-200727010-00005

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

59-66

issue

1

eissn

1173-2563

issn

1179-1918

pii

2715

journal_volume

27

pub_type

临床试验,杂志文章,多中心研究
  • Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.

    abstract:BACKGROUND AND OBJECTIVE:Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s40261-016-0478-8

    authors: Fujita K,Kaneko M,Narukawa M

    更新日期:2017-03-01 00:00:00

  • Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome.

    abstract:BACKGROUND:To evaluate the efficacy and safety of bronchoalveolar lavage (BAL) with diluted porcine surfactant in mechanically ventilated term infants with severe acute respiratory distress syndrome (ARDS) due to meconium aspiration syndrome (MAS). METHODS:Eight consecutive mechanically ventilated term infants with se...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200626010-00002

    authors: Lista G,Bianchi S,Castoldi F,Fontana P,Cavigioli F

    更新日期:2006-01-01 00:00:00

  • Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.

    abstract:BACKGROUND:Warfarin is a commonly used oral anticoagulant and its interaction with other drugs can result in serious thrombotic or bleeding events. Currently, there is no definitive evidence on the possibility of an interaction between warfarin and oseltamivir. OBJECTIVE:The objective of this study was to investigate ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11595860-000000000-00000

    authors: Lee SH,Kang HR,Jung JW,Kwon JW,Hong KS,Yu KS,Cho SH

    更新日期:2012-02-01 00:00:00

  • Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.

    abstract:BACKGROUND AND OBJECTIVE:Gemigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. This study evaluated possible pharmacodynamic and pharmacokinetic interactions between gemigliptin and metformin and investigated their tolerability. METHODS:A randomized, open-la...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-014-0184-3

    authors: Shin D,Cho YM,Lee S,Lim KS,Kim JA,Ahn JY,Cho JY,Lee H,Jang IJ,Yu KS

    更新日期:2014-06-01 00:00:00

  • Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.

    abstract:BACKGROUND AND OBJECTIVES:Bilastine is a novel second-generation antihistamine for the symptomatic treatment of allergic rhinitis and urticaria. The objective of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of bilastine following single and multiple oral doses in healthy Japanese ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-016-0447-2

    authors: Togawa M,Yamaya H,Rodríguez M,Nagashima H

    更新日期:2016-12-01 00:00:00

  • Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.

    abstract:BACKGROUND AND OBJECTIVES:Oxycodone tamper resistant (OTR) is a new extended-release abuse-deterrent formulation providing improvements in the tamper resistant characteristics. This study aimed to investigate the pharmacokinetic properties of the new OTR tablets and evaluate the bioequivalence of oxycodone from OTR and...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-019-00870-w

    authors: Luo Z,Miao J,Shu S,Wang Y,Zhu X,Hu C,Shen Y

    更新日期:2020-02-01 00:00:00

  • Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study.

    abstract:BACKGROUND AND OBJECTIVE:This real-world study assessed the prevalence, risk factors for, and incidence of seizures in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS:Patients with mCRPC were selected from MarketScan Commercial and Medicare Supplemental Databases between 1 January 2009 a...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0578-0

    authors: Dharmani C,Bonafede M,Krivoshik A

    更新日期:2017-12-01 00:00:00

  • A Literature Review of Psychotropic Medications and Alcohol as Risk Factors for Falls in Community Dwelling Older Adults.

    abstract::Psychotropic medications and alcohol are potential risk factors for falls in older adults. However, there has been no appraisal of the literature on whether these medications, both singly and in combination with alcohol, are associated with falls in community dwelling older adults (those aged 60 years and older living...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-018-0721-6

    authors: Laberge S,Crizzle AM

    更新日期:2019-02-01 00:00:00

  • Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis.

    abstract:BACKGROUND:Among the many consequences of loss of CFTR protein function, a significant reduction of the secretion of bicarbonate (HCO3-) in cystic fibrosis (CF) is a major pathogenic feature. Loss of HCO3- leads to abnormally low pH and impaired mucus clearance in airways and other exocrine organs, which suggests that ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00861-x

    authors: Gomez CCS,Parazzi PLF,Clinckspoor KJ,Mauch RM,Pessine FBT,Levy CE,Peixoto AO,Ribeiro MÂGO,Ribeiro AF,Conrad D,Quinton PM,Marson FAL,Ribeiro JD

    更新日期:2020-02-01 00:00:00

  • Barriers to pain management: focus on opioid therapy.

    abstract::Despite the availability of effective pain treatments, there are numerous barriers to effective management resulting in a large proportion of patients not achieving optimal pain control. Chronic pain is inadequately treated because of a combination of cultural, societal, educational, political and religious constraint...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11630040-000000000-00000

    authors: Zuccaro SM,Vellucci R,Sarzi-Puttini P,Cherubino P,Labianca R,Fornasari D

    更新日期:2012-02-22 00:00:00

  • Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.

    abstract:BACKGROUND AND OBJECTIVE:Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS initiating golimumab ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00959-7

    authors: Ziyadeh NJ,Geldhof A,Noël W,Otero-Lobato M,Esslinger S,Chakravarty SD,Wang Y,Seeger JD

    更新日期:2020-11-01 00:00:00

  • Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study.

    abstract:BACKGROUND:NSAIDs are widely used to treat fever and pain in children, but their possible role in the progression of some bacterial infections is controversial. OBJECTIVE:This study was performed to analyse reported cases of severe bacterial infection associated with NSAID exposure in children admitted for this reason...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11532890-000000000-00000

    authors: Leroy S,Marc E,Bavoux F,Tréluyer JM,Gendrel D,Bréart G,Pons G,Chalumeau M

    更新日期:2010-01-01 00:00:00

  • Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers.

    abstract:BACKGROUND AND OBJECTIVE:Dobutamine causes an increase in cardiac output (CO) by augmenting stroke volume (SV) through enhanced left ventricular contractility and by decreasing systemic vascular resistance. However, in some patients, the dominant mechanism by which dobutamine improves left ventricular performance is an...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200828020-00006

    authors: Ahonen J,Aranko K,Iivanainen A,Maunuksela EL,Paloheimo M,Olkkola KT

    更新日期:2008-01-01 00:00:00

  • Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects.

    abstract:BACKGROUND AND OBJECTIVE:Following oral administration of abiraterone acetate, the parent compound abiraterone acetate is rapidly metabolized to abiraterone. To our knowledge, bioanalytical methods to date have not been able to detect the parent compound in human plasma, and bioassay was only performed on the metabolit...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40261-019-00752-1

    authors: Bouhajib M,Tayab Z

    更新日期:2019-03-01 00:00:00

  • Effect of Levothyroxine Treatment on Incident Dementia in Adults with Atrial Fibrillation and Hypothyroidism.

    abstract:BACKGROUND AND OBJECTIVE:The possible adverse or positive effects of levothyroxine treatment among patients with atrial fibrillation have been debated. Atrial fibrillation, levothyroxine treatment, and dementia are common among older adults, yet little is known about the effects of levothyroxine on the development of d...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0740-3

    authors: Wändell P,Carlsson AC,Sundquist J,Sundquist K

    更新日期:2019-02-01 00:00:00

  • Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.

    abstract:BACKGROUND AND OBJECTIVE:Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/BF03256918

    authors: Witthaut J,Bushmakin AG,Gerber RA,Cappelleri JC,Le Graverand-Gastineau MP

    更新日期:2011-11-01 00:00:00

  • Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

    abstract::Page 806, column 1, line 3: The text, which previously read. ...

    journal_title:Clinical drug investigation

    pub_type: 已发布勘误

    doi:10.1007/s40261-020-00892-9

    authors: Lyseng-Williamson KA

    更新日期:2020-03-01 00:00:00

  • Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain.

    abstract:BACKGROUND:NSAIDs are widely used for patients presenting with low back pain. A quick-release formulation of lornoxicam, a potent NSAID from the chemical class of oxicams, offers a faster onset of pain relief compared with the standard tablet formulation. METHODS:Time to onset of pain relief with lornoxicam was compar...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200626050-00004

    authors: Yakhno N,Guekht A,Skoromets A,Spirin N,Strachunskaya E,Ternavsky A,Olsen KJ,Moller PL

    更新日期:2006-01-01 00:00:00

  • Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.

    abstract:BACKGROUND AND OBJECTIVE:Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing of exposure. METHODS:The UK Health Improvement Network primary care database was used to perform a nested case-control st...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0729-y

    authors: Morales DR,Slattery J,Pacurariu A,Pinheiro L,McGettigan P,Kurz X

    更新日期:2019-02-01 00:00:00

  • Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.

    abstract:BACKGROUND:Dutasteride is a dual inhibitor of type I and type II 5α-reductases and provides nearly complete suppression of dihydrotestosterone, which plays a key role in the aetiology and development of benign prostatic hyperplasia (BPH). Most knowledge about the efficacy and safety of dutasteride in BPH derives from t...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11593750-000000000-00000

    authors: Na Y,Ye Z,Zhang S,Chinese Dutasteride Phase III Trial (ARIA108898) Study Group.

    更新日期:2012-01-01 00:00:00

  • Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.

    abstract:BACKGROUND AND OBJECTIVE:Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0275-9

    authors: McLaughlin MM,Ammar AT,Gerzenshtein L,Scarsi KK

    更新日期:2015-04-01 00:00:00

  • US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.

    abstract::Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall,...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0492-5

    authors: Boyd SD,Tracy L,Komatsu TE,Harrington PR,Viswanathan P,Murray J,Sherwat A

    更新日期:2017-04-01 00:00:00

  • Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates.

    abstract:BACKGROUND AND OBJECTIVE:Bisphosphonates are commonly used to treat and prevent osteoporosis. These compounds have unusual pharmacokinetic characteristics because they bind strongly to bone, and a portion becomes buried under newly formed bone. Once incorporated into bone tissue, the subsequent release during bone remo...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525020-00003

    authors: Lasseter KC,Porras AG,Denker A,Santhanagopal A,Daifotis A

    更新日期:2005-01-01 00:00:00

  • Budget Impact Analysis of Brivaracetam Adjunctive Therapy for Partial-Onset Epileptic Seizures in Valencia Community, Spain.

    abstract:BACKGROUND AND OBJECTIVE:More than 30% of patients with epilepsy have inadequate control of seizures with drug therapy. The goal of this study is to determine the budget impact (BI) of the introduction of brivaracetam to the portfolio of approved drugs in Spain as adjunctive therapy for the treatment of partial-onset e...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0615-z

    authors: Barrachina-Martínez I,Vivas-Consuelo D,Piera-Balbastre A

    更新日期:2018-04-01 00:00:00

  • Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.

    abstract:BACKGROUND AND OBJECTIVES:As compared with individual tablets, saxagliptin/metformin extended-release (XR) fixed-dose combination (FDC) tablets offer potential for increased patient compliance with the convenience of once-daily dosing. Two bioequivalence studies assessed the fed-state bioequivalence of saxagliptin/metf...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11590290-000000000-00000

    authors: Boulton DW,Smith CH,Li L,Huang J,Tang A,LaCreta FP

    更新日期:2011-01-01 00:00:00

  • Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

    abstract::This narrative review summarises the benefits, risks and appropriate use of acid-suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences. It focuses on current controversies on ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-017-0519-y

    authors: Fisher L,Fisher A

    更新日期:2017-07-01 00:00:00

  • Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database.

    abstract:BACKGROUND AND OBJECTIVE:Several cases of facial paralysis have been reported following influenza vaccination; however, recent surveillance studies have not shown an increased risk. In this study, we analyzed the vaccine adverse event reporting system (VAERS) data to determine whether the facial paralysis reporting rat...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00952-0

    authors: Kamath A,Maity N,Nayak MA

    更新日期:2020-09-01 00:00:00

  • Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study.

    abstract:BACKGROUND AND OBJECTIVE:There is a general concern about the use of multisource (generic) antibacterials in the clinical setting with registration based solely on bioequivalence data. In order to address this concern, two modified-release formulations of clarithromycin (i.e. the originator Klacid XL and the generic Kl...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200929040-00005

    authors: Snyman JR,Schoeman HS,Grobusch MP,Henning M,Rabie W,Hira M,Parshotam K,Mithal Y,Singh S,Ramdas Z

    更新日期:2009-01-01 00:00:00

  • Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional study.

    abstract:OBJECTIVE:The aim of this study was to confirm randomized clinical trial results showing that a fixed timolol/travoprost combination (TT; DuoTrav) controls intraocular pressure (IOP) better than a fixed timolol/latanoprost combination (TL; Xalacom) in everyday ophthalmic practice, when measured in the morning and >24 h...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/0044011-200828120-00004

    authors: Denis P,Lafuma A,Jeanbat V,Laurendeau C,Berdeaux G

    更新日期:2008-01-01 00:00:00

  • Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization.

    abstract:BACKGROUND AND OBJECTIVES:A new oral antidiabetic drug class, sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), has been covered by national health insurance in Taiwan since May 2016. This study estimated the impacts of insurance coverage for SGLT-2 inhibitors on the replacement effects of antidiabetic dr...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0689-2

    authors: Chen HY,Chiu PY,Chang CJ,Tsai LL,Huang YL,Hsu JC

    更新日期:2018-12-01 00:00:00